Ghrelin, a novel therapy, corrects cytokine and NF-κB-AKT-MAPK network and mitigates intestinal injury induced by combined radiation and skin-wound trauma
Abstract
Compared to radiation injury alone (RI), radiation injury combined wound (CI) further enhances acute radiation syndrome and subsequently mortality. We previously reported that therapy with Ghrelin, the 28-amino-acid-peptide secreted from the stomach, significantly increased 30-day survival and mitigated hematopoietic death by enhancing and sustaining granulocyte-colony stimulating factor (G-CSF) and keratinocyte chemoattractant (KC) in the blood and bone marrow; increasing circulating white blood cell depletion; inhibiting splenocytopenia; and accelerating skin-wound healing on day 30 after CI. Herein, we aimed to study the efficacy of Ghrelin on intestinal injury at early time points after CI.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- May 12, 2020
- Source ID
- 10.1186/s13578-020-00425-z
Entities
People
- Connie Ho
- Georgetta Cannon
- Joan T. Smith
- Juliann G Kiang
- Mang Xiao
- Marsha N. Anderson
- Min Zhai
- Wanchang Cui
Organizations
- Armed Forces Radiobiology Research Institute
- National Institute of Allergy and Infectious Diseases